Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
GPCR Structure Therapeutics	$19.14 +0.7%	$19.11	$13.22 ▼ $45.37	$1.10B	-1.89	861,701 shs	429,948 shs
LFCR Lifecore Biomedical	$7.62 +1.2%	$7.63	$3.68 ▼ $8.85	$285.06M	0.65	212,511 shs	75,742 shs
NTLA Intellia Therapeutics	$11.60 +1.6%	$11.20	$5.90 ▼ $23.76	$1.25B	2.31	4.09 million shs	3.76 million shs
ZYME Zymeworks	$14.84 -0.6%	$13.36	$9.03 ▼ $17.70	$1.12B	1.26	527,881 shs	796,955 shs

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
GPCR Structure Therapeutics	+0.96%	+2.32%	+4.00%	-15.25%	-53.74%
LFCR Lifecore Biomedical	+0.40%	+4.01%	+2.73%	+9.93%	+58.86%
NTLA Intellia Therapeutics	+0.53%	+11.85%	-12.89%	+53.29%	-50.22%
ZYME Zymeworks	+0.67%	+4.26%	+10.92%	+31.54%	+29.04%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
GPCR Structure Therapeutics	2.7111 of 5 stars	3.5	3.0	0.0	2.4	1.7	0.6
LFCR Lifecore Biomedical	0.8675 of 5 stars	1.3	0.0	0.0	2.4	4.2	0.6
NTLA Intellia Therapeutics	4.5411 of 5 stars	4.3	1.0	4.7	2.4	3.3	0.6
ZYME Zymeworks	1.3287 of 5 stars	3.5	0.0	0.0	0.6	1.7	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
GPCR Structure Therapeutics	3.00	Buy	$75.71	295.58% Upside
LFCR Lifecore Biomedical	2.67	Moderate Buy	$8.00	4.99% Upside
NTLA Intellia Therapeutics	2.58	Moderate Buy	$29.05	150.45% Upside
ZYME Zymeworks	2.90	Moderate Buy	$21.43	44.40% Upside

Current Analyst Ratings Breakdown

Latest LFCR, ZYME, GPCR, and NTLA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/13/2025	NTLA Intellia Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$14.00
8/11/2025	NTLA Intellia Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$68.00 ➝ $60.00
8/11/2025	ZYME Zymeworks	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$19.00 ➝ $22.00
8/8/2025	NTLA Intellia Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$50.00 ➝ $45.00
8/8/2025	NTLA Intellia Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$25.00 ➝ $21.00
8/8/2025	NTLA Intellia Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$30.00 ➝ $25.00
8/7/2025	GPCR Structure Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$75.00 ➝ $60.00
8/7/2025	GPCR Structure Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$92.00 ➝ $90.00
8/7/2025	GPCR Structure Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Market Outperform ➝ Market Outperform	$89.00 ➝ $87.00
7/3/2025	ZYME Zymeworks	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$13.00
6/23/2025	GPCR Structure Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$65.00

(Data available from 8/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
GPCR Structure Therapeutics	N/A	N/A	N/A	N/A	$13.40 per share	N/A
LFCR Lifecore Biomedical	$128.87M	2.21	N/A	N/A	$0.04 per share	190.50
NTLA Intellia Therapeutics	$52.86M	23.56	N/A	N/A	$6.66 per share	1.74
ZYME Zymeworks	$122.87M	9.08	N/A	N/A	$6.63 per share	2.24

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
GPCR Structure Therapeutics	-$122.53M	-$1.05	N/A	N/A	N/A	N/A	-21.31%	-20.34%	11/12/2025 (Estimated)
LFCR Lifecore Biomedical	-$38.72M	-$1.31	N/A	N/A	N/A	-31.70%	-846.51%	-13.03%	10/3/2025 (Estimated)
NTLA Intellia Therapeutics	-$519.02M	-$4.69	N/A	N/A	N/A	-908.48%	-57.48%	-45.04%	11/6/2025 (Estimated)
ZYME Zymeworks	-$118.67M	-$0.97	N/A	N/A	N/A	-182.75%	-23.00%	-18.04%	10/30/2025 (Estimated)

Latest LFCR, ZYME, GPCR, and NTLA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/7/2025	Q4 2025	LFCR Lifecore Biomedical	-$0.09	-$0.10	-$0.01	-$0.06	$35.36 million	$36.44 million
8/7/2025	Q2 2025	NTLA Intellia Therapeutics	-$1.03	-$0.99	+$0.04	-$0.98	$12.26 million	$14.25 million
8/7/2025	N/A	ZYME Zymeworks	-$0.52	$0.03	+$0.55	N/A	$17.18 million	$48.73 million
8/6/2025	Q2 2025	GPCR Structure Therapeutics	-$0.28	-$0.36	-$0.08	-$0.36	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
GPCR Structure Therapeutics	N/A	N/A	N/A	N/A	N/A
LFCR Lifecore Biomedical	N/A	N/A	N/A	N/A	N/A
NTLA Intellia Therapeutics	N/A	N/A	N/A	N/A	N/A
ZYME Zymeworks	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
GPCR Structure Therapeutics	N/A	20.48	20.48
LFCR Lifecore Biomedical	113.76	2.84	1.77
NTLA Intellia Therapeutics	N/A	5.19	5.19
ZYME Zymeworks	N/A	4.10	4.10

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
GPCR Structure Therapeutics	91.78%
LFCR Lifecore Biomedical	83.36%
NTLA Intellia Therapeutics	88.77%
ZYME Zymeworks	92.89%

Insider Ownership

Company	Insider Ownership
GPCR Structure Therapeutics	5.60%
LFCR Lifecore Biomedical	32.20%
NTLA Intellia Therapeutics	3.10%
ZYME Zymeworks	1.92%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
GPCR Structure Therapeutics	136	57.60 million	54.37 million	Optionable
LFCR Lifecore Biomedical	690	37.41 million	25.36 million	Optionable
NTLA Intellia Therapeutics	600	107.35 million	104.02 million	Optionable
ZYME Zymeworks	460	75.17 million	67.56 million	Optionable

LFCR, ZYME, GPCR, and NTLA Headlines

Recent News About These Companies

Zymeworks Reports Q2 Results and FDA Clearance

August 19, 2025 | theglobeandmail.com

Zymeworks Announces Participation in Upcoming Investor Conferences

August 19, 2025 | globenewswire.com

Zymeworks Inc. (NYSE:ZYME) Shares Purchased by Tejara Capital Ltd

August 17, 2025 | marketbeat.com

Zymeworks Earnings Call: Revenue Surge and Strategic Gains

August 13, 2025 | msn.com

Zymeworks (ZYME) Could Find a Support Soon, Here's Why You Should Buy the Stock Now

August 12, 2025 | zacks.com

Citigroup Raises Zymeworks (NYSE:ZYME) Price Target to $22.00

August 12, 2025 | marketbeat.com

Q1 Earnings Estimate for Zymeworks Issued By Lifesci Capital

August 12, 2025 | marketbeat.com

Zymeworks Inc.: Zymeworks Strengthens Board of Directors with Appointments of Greg Ciongoli and Robert E. Landry

August 11, 2025 | finanznachrichten.de

Zymeworks Strengthens Leadership with New Board Appointments

August 11, 2025 | tipranks.com

Zymeworks Inc. Appoints Greg Ciongoli and Robert E. Landry to Board of Directors

August 11, 2025 | quiverquant.comQ

Zymeworks Strengthens Board of Directors with Appointments of Greg Ciongoli and Robert E. Landry

August 11, 2025 | financialpost.comF

Zymeworks Strengthens Board of Directors with Appointments of Greg Ciongoli and Robert E. Landry

August 11, 2025 | globenewswire.com

Zymeworks Inc. (NYSE:ZYME) Receives Average Rating of "Moderate Buy" from Analysts

August 11, 2025 | marketbeat.com

Earnings Beat: Zymeworks Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

August 10, 2025 | finance.yahoo.com

Zymeworks (NYSE:ZYME) Announces Earnings Results, Beats Expectations By $0.55 EPS

August 9, 2025 | marketbeat.com

Zymeworks signals expanded royalty streams and milestone-driven cash infusions through new approvals and pipeline progression

August 8, 2025 | msn.com

Zymeworks Inc. (ZYME) Q2 2025 Earnings Call Transcript

August 8, 2025 | seekingalpha.com

Zymeworks Inc. (ZYME) Tops Q2 Earnings and Revenue Estimates

August 7, 2025 | zacks.com

Zymeworks Provides Corporate Update and Reports Second Quarter 2025 Financial Results

August 7, 2025 | globenewswire.com

Zymeworks (ZYME) Projected to Post Earnings on Thursday

July 31, 2025 | marketbeat.com

Bispecific Antibodies Market Report 2025- 2035, with Profiles of Akeso Biopharma, Alexion, Amgen, Genmab, Immunocore, Linton Pharm, Merck, OncXerna Therapeutics, Zymeworks, and ...

July 30, 2025 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

LFCR, ZYME, GPCR, and NTLA Company Descriptions

Structure Therapeutics NASDAQ:GPCR

$19.14 +0.14 (+0.74%)

Closing price 04:00 PM Eastern

Extended Trading

$19.12 -0.02 (-0.10%)

As of 05:27 PM Eastern

Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. It is also developing oral small molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073, a biased agonist for apelin receptor, a GPCR that has been implicated in idiopathic pulmonary fibrosis (IPF); and LTSE-2578, an investigational oral small molecule lysophosphatidic acid 1 receptor antagonist for the treatment of IPF and PPF. The company was formerly known as ShouTi Inc. Structure Therapeutics Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

Lifecore Biomedical NASDAQ:LFCR

$7.62 +0.09 (+1.20%)

Closing price 04:00 PM Eastern

Extended Trading

$7.61 -0.01 (-0.13%)

As of 04:11 PM Eastern

Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally. The company engages in the manufacturing of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures. It also provides services, such as technology development, material component changes, analytical method development, formulation development, pilot studies, stability studies, process validation, and production of materials for clinical studies to its partners for HA-based and non-HA based aseptically formulated and filled products. The company was formerly known as Landec Corporation and changed its name to Lifecore Biomedical, Inc. in November 2022. Lifecore Biomedical, Inc. was founded in 1965 and is headquartered in Chaska, Minnesota.

Intellia Therapeutics NASDAQ:NTLA

$11.60 +0.18 (+1.58%)

Closing price 04:00 PM Eastern

Extended Trading

$11.62 +0.02 (+0.17%)

As of 05:46 PM Eastern

Intellia Therapeutics, Inc., a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease. It also focusses on programs comprising hemophilia A and hemophilia B; and research of proprietary programs focused on developing engineered cell therapies to treat various cancers and autoimmune diseases. In addition, the company offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. It has license and collaboration agreement with Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies, and co-develop and co-commercialize allogeneic universal CAR-T cell products for an immuno-oncology indication; SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of a variety of B cell-mediated autoimmune diseases; and ONK Therapeutics, Ltd. for the development of engineered NK cell therapies to cure patients with cancer. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Zymeworks NYSE:ZYME

$14.84 -0.09 (-0.60%)

Closing price 04:00 PM Eastern

Extended Trading

$14.84 +0.01 (+0.03%)

As of 05:36 PM Eastern

Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. It also develops a pipeline of preclinical product candidates and discovery-stage programs in oncology, including immuno-oncology agents and other therapeutic areas. Zymeworks Inc. has strategic partnerships and collaborations with BeiGene, Ltd.; Celgene Corporation; Celgene Alpine Investment Co. LLC; GlaxoSmithKline Intellectual Property Development Limited; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; LEO Pharma A/S; Iconic Therapeutics, Inc.; Merck Sharp & Dohme Research GmbH; and Atreca, Inc. Zymeworks Inc. was incorporated in 2003 and is based in Middletown, Delaware.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time